medical research

The NYSE Welcomes vVARDIS as a Publicly Listed Company

NEW YORK, Nov. 14, 2026 /PRNewswire/ -- vVARDIS (NYSE: VVVV) co-founders Dr. Haley Abivardi and Dr. Goly Abivardi aim to reshape the future of dental care with a drill-free treatment for the world's #1 non-communicable disease: cavities. vVARDIS Solves a Problem that Millions FaceTooth decay affects billions of people worldwide, and dental anxiety keeps millions from getting the care they need.vVARDIS is a Swiss...

MacKay and Tri-Service General Hospitals Name First Winners of Taiwan’s T+ MedIC Medical Innovation Accelerator

TAIPEI, Nov. 13, 2026 /PRNewswire/ -- An AI tool that helps clinicians read electrocardiograms and a screening platform that pairs low-dose chest CT with artificial intelligence won the top prizes at the first final round of the T+ MedIC Accelerator, a health-tech accelerator that brings together a private and a public medical center in Taiwan.The accelerator (T+ MedIC Accelerator,)  was founded by MacKay Memorial Hospital and Tri-Service...

Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader

SYDNEY, Nov. 12, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity and overcome treatment resistance, today announced that it will host a virtual event on Wednesday, December 2, 2026 at 4:00 PM ET featuring management's overview of NDL2, the Company's novel nuclear PD-L1...

Antengene Presents Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Nov. 12, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it has presented the latest preclinical results of ATG-207...

TriNetX Launches Human-Validated Fact Extraction from Clinical Notes Data Researchers Can Trust

CAMBRIDGE, Mass., Nov. 10, 2026 /PRNewswire/ -- As artificial intelligence (AI) makes extracting information from clinical notes easier than ever, the harder question for researchers is whether those data can be trusted for real-world evidence. TriNetX®, the world's leading federated health data network, today announced NLP-extracted Facts from Clinical Notes, now available in the TriNetX LIVE™ platform and in downloadable datasets. The...

Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease

TOKYO, Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NTDs) and emerging & re-emerging infectious diseases such as Ebola disease. 2 Investment of approx. JPY 450 million (USD 2.9 million1) for Clinical...

CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent years become a frontier topic in the life sciences and medicine. A new study led by researchers at City University of Hong Kong (CityUHK) has found that...

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced a major clinical validation milestone for CS2009, its investigational PD-1/VEGF/CTLA-4 trispecific antibody, following two Rapid Oral presentations at the European...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, today announced that it has presented the latest clinical results from the Phase II study of...

Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent

FLORENCE, Italy and GAITHERSBURG, Md., Oct. 22, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with Georgiamune Inc., a clinical-stage biotechnology company discovering and developing first-in-class...

New hair transplant review challenges fixed donor limits

MANHATTAN BEACH, Calif., Oct. 22, 2026 /PRNewswire/ -- Dr. U Hair and Skin Clinic in the Los Angeles area reports that a new clinical review led by Sanusi Umar, MD, challenges reliance on fixed maps to define hair transplant donor areas. The open-access paper, "Redefining the Safe Donor Area in Follicular Unit Excision: Toward Dynamic, Patient-Specific Zones," was published Oct. 16 in the Journal of Cosmetic Dermatology.

[China’s Voice] Preclinical Animal Study: Domestic Neurointerventional Robotic System PANVIS STAR® Completes Validation of Five Major Neurointerventional Procedures

SHANGHAI, Oct. 22, 2026 /PRNewswire/ -- Neurointerventional robots have long remained at the stage of "only being able to assist with angiography." Through close medical-engineering collaboration with Professor Jianmin Liu's team at Shanghai Changhai Hospital, Shenzhen Institute of Advanced Biomedical Robot Co., Ltd. independently developed a new-generation vascular interventional surgical robot technology and product platform, PANVIS STAR®,...

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

DUBLIN, Oct. 22, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis (ECP), announced today that its THERAKOS™ CELLEX™ Photopheresis System has received certification under the EU MDR for an expanded indication. The system is now indicated in Europe for the treatment of immune-related adverse events (irAEs) associated with immune...

Telix Reports Third Quarter 2026 Financial Performance

MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026). Q3 2026 Highlights[1]Group revenue of US$245 million increased 19% over the prior corresponding quarter (Q3 2025) driven by continued strong...

Patronus Biotech Receives Ethical Approval to Begin First-in-Human Phase 1 Trial of Three Multi-Stage Vaccines Against Malaria in Australia

GUANGZHOU, China, Oct. 20, 2026 /PRNewswire/ -- Patronus Biotech, a biotechnology company that develops next-generation vaccines to address unmet global needs, today announced that its Phase I first-in-human clinical trial NCT07831226 of three novel multi-stage VLP-based investigational vaccine candidates for malaria has received ethical approval from Bellberry Limited on 19 October 2026. LYB014 targets 3 key stages of the Plasmodium...

New Innovative Molecular Technology Combination “LAMP + CRISPR” as CE-IVD

MUNICH, Oct. 20, 2026 /PRNewswire/ -- AmplexDiagnostics and Scope Biosciences are proud to introduce a groundbreaking solution in molecular diagnostics. In a new approach, "eazySNP" combines the highly specialized molecular technologies LAMP and CRISPR. By integrating these two methods, eazySNP enables the rapid and highly specific detection of genetic variants. This technological synergy was made possible through the scientific collaboration...

Colossal to Repatriate Rare Moa Egg to Aotearoa (New Zealand)

CHRISTCHURCH, New Zealand and DALLAS, Oct. 20, 2026 /PRNewswire/ -- Colossal Biosciences, the world's first de-extinction company, today announced that it has acquired a rare giant moa egg from a private collection in the United States for the sole purpose of returning it to Aotearoa (New Zealand). Colossal plans to present the egg to Professor Te Maire Tau (Ūpoko of Ngāi Tūāhuriri, a hapu of Ngāi Tahu), a distinguished Māori historian,...

Can we produce low-cost omega-3s without relying on fish?

GOLD COAST, Australia, Oct. 20, 2026 /PRNewswire/ -- Southern Cross University researchers are aiming to halve the cost of producing omega-3 supplements to make these essential nutrients more accessible to pregnant women and infants in low-income countries, backed by the University's first-ever grant from The Gates Foundation.The research takes a novel approach: rather than relying on fish oil, the team is going closer to the original source...

CHANDO Group Showcases Chinese Beauty Science at COSMETIC 360, Debuts Fatigue-Aging Research on Global Stage

PARIS, Oct. 19, 2026 /PRNewswire/ -- CHANDO Group featured its five brands and latest advances in cosmetic ingredient research at the 12th edition of COSMETIC 360, organized by Cosmetic Valley and held at the Louvre in Paris on October 14–15. As a representative of China's beauty industry, the Group also participated in the 2026 International Cosmetics Innovation Summit (INPD). At the event, CHANDO Group presented its findings on fatigue-...

UEG Week 2026: Antibiotic use from childhood linked to higher odds of IBS in young adulthood

BARCELONA, Spain, Oct. 19, 2026 /PRNewswire/ -- Antibiotic use from childhood through early adulthood is associated with higher odds of irritable bowel syndrome (IBS) at age 24, with the odds increasing as the number of antibiotic prescriptions rose, according to a new study presented today at UEG Week 2026.Researchers analysed data from 2,853 participants in the Swedish BAMSE birth cohort. Antibiotic prescriptions were obtained from the...

Four Leading Institutions Complete Initial Clinical Experience with Spectrum Dynamics Medical’s All-Energy Digital SPECT/CT

MORGES, Switzerland, Oct. 16, 2026 /PRNewswire/ -- Spectrum Dynamics Medical today announced the completion of initial clinical experience with the All-Energy Enhancement for the VERITON-CT 400 Series at four leading institutions. The work demonstrated high-energy theranostics imaging without compromising diagnostic performance. Following this milestone, the system enhancement, launched in July 2026, will now be known as the VERITON-CT 400...

Opella: New study demonstrates successful cough treatment extends beyond symptom relief

PARIS, Oct. 15, 2026 /PRNewswire/ -- A new real-world study from Opella, the maker of Mucosolvan and Bisolvon, provides pharmacists with compelling evidence that the success of a cough treatment should be measured by its impact on a patient's overall well-being, alongside traditional symptomatic relief.With most consumers1 making treatment decisions in the pharmacy, the pharmacist's recommendation plays a pivotal role in helping patients...

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna, Austria from October 17-21, 2026.Dr. David N. Cade, Telix Group Chief Medical Officer, said, "Our expansive presence at EANM reflects the...

Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform.ALK7, encoded by the ACVR1C gene, is predominantly expressed in adipose tissue and is a genetically validated target for...

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company to initiate a phase II clinical trial for influenza prevention in general population in the United States.Addressing Gaps in Influenza...

SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease

LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting stents (DES) in patients with complex coronary artery disease.Designed to generate comparative evidence, SPARX aims to address key unanswered clinical...

T-MAXIMUM’s B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for the treatment of patients with brain metastases from lung cancer and breast cancer.This is the second Phase 2 study of MT027 to receive FDA clearance....

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will release the latest preclinical results of ATG-207...

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology approaches with AstraZeneca (LSE/STO/NYSE: AZN). PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency (HRD) in...

OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetration of tyrosine kinase inhibitors (TKIs).OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are...

Stay up to date

On all things Queensland

Please wait...

Thank you for sign up!